100 related articles for article (PubMed ID: 18265670)
1. FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
Yonemori K; Okusaka T; Ueno H; Morizane C; Takesako Y; Ikeda M
Hepatogastroenterology; 2007 Dec; 54(80):2383-6. PubMed ID: 18265670
[TBL] [Abstract][Full Text] [Related]
2. 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese Cooperative Study.
Nose H; Okada S; Okusaka T; Furuse J; Yoshino M; Ogoshi K; Kato T; Miyaji M; Hoshino M; Ariyama J; Suyama M; Karasawa E; Yoshimori M
Hepatogastroenterology; 1999; 46(30):3244-8. PubMed ID: 10626195
[TBL] [Abstract][Full Text] [Related]
3. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
Sasada T; Denno R; Tanaka T; Kanai M; Mizukami Y; Kohno S; Takabayashi A
Am J Clin Oncol; 2008 Feb; 31(1):71-8. PubMed ID: 18376231
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
5. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
6. Predictors of systemic chemotherapy contraindication in pancreatic cancer patients with distant metastasis.
Zhang Y; Dang C; Ma Q; Chen W; Nagata K
Hepatogastroenterology; 2007; 54(73):254-9. PubMed ID: 17419272
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Li M; Zhang J; Wang D; Zhong B; Tucker S; Lu C; Cheng J; Cao C; Xu J; Xu J; Pan H
Anticancer Drugs; 2009 Nov; 20(10):941-5. PubMed ID: 19745719
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
Al-Batran SE; Hartmann JT; Probst S; Schmalenberg H; Hollerbach S; Hofheinz R; Rethwisch V; Seipelt G; Homann N; Wilhelm G; Schuch G; Stoehlmacher J; Derigs HG; Hegewisch-Becker S; Grossmann J; Pauligk C; Atmaca A; Bokemeyer C; Knuth A; Jäger E;
J Clin Oncol; 2008 Mar; 26(9):1435-42. PubMed ID: 18349393
[TBL] [Abstract][Full Text] [Related]
11. A case of pancreatic cancer achieving symptomatic improvement with systemic chemotherapy.
Kosakamoto H; Okada S; Ueno H; Okusaka T; Ikeda M; Tanaka N; Yoshimori M; Matsuno Y
Hepatogastroenterology; 1999; 46(28):2621-4. PubMed ID: 10522052
[TBL] [Abstract][Full Text] [Related]
12. Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
Milandri C; Calzolari F; Passardi A; Tison C; Giampalma E; Cecconetto L; Golfieri R
Hepatogastroenterology; 2007 Dec; 54(80):2373-7. PubMed ID: 18265668
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
Xiong HQ; Varadhachary GR; Blais JC; Hess KR; Abbruzzese JL; Wolff RA
Cancer; 2008 Oct; 113(8):2046-52. PubMed ID: 18756532
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
Turrini O; Viret F; Moureau-Zabotto L; Guiramand J; Moutardier V; Lelong B; de Chaisemartin C; Giovannini M; Delpero JR
Oncology; 2009; 76(6):413-9. PubMed ID: 19407474
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience.
Schomas DA; Miller RC; Donohue JH; Gill S; Thurmes PJ; Haddock MG; Quevedo JF; Gunderson LL
Ann Surg; 2009 Apr; 249(4):588-95. PubMed ID: 19300231
[TBL] [Abstract][Full Text] [Related]
20. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
